The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,000
From Biomarkers to New Treatments for Post-Traumatic Stress Disorder
Wong, A. H. C., Wang, L., Shen, Y., & Liu, F. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01617-2 · Cited by 1
The Transformation of Post-Traumatic Stress Disorder: From Neurosis to Neurobiology
Tanja, C., & Boadie, W. (2011) · InTech eBooks · doi:10.5772/20810 · Cited by 1
Chapter 4.7 The pharmacology of anxiolysis
Holmes, A. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00016-1 · Cited by 1
Brain Interactions between Extinction and Reconsolidation in the Treatment of Fear Memories
Sartor, D., Fiorenza, N. G., Myskiw, J. D. C., & Izquierdo, I. (2011) · Neuroscience & Medicine · doi:10.4236/nm.2011.23032 · Cited by 1
Experimentelle Behandlungsverfahren bei Angsterkrankungen - Einblick in die Therapieforschung
Vennewald, N., Diemer, J., Fallgatter, A. J., Mühlberger, A., Ströhle, A., & Zwanzger, P. (2013) · Die Psychiatrie · doi:10.1055/s-0038-1670893 · Cited by 1
D-Cycloserine Augmentation of Cognitive-Behavioral Therapy for the Treatment of Anxiety Disorders
Janicak, P. G., Dattilo, N. C., Manos, R. C., Storch, E. A., & Goddard, A. W. (2011) · Psychopharm Review · doi:10.1097/01.psyphr.0000399653.06660.fa · Cited by 1
Evaluating Strategies for Combining Pharmacotherapy with Cognitive Behavioral Therapy
Charney, M. E., Calkins, A. W., Hallion, L. S., & Simon, N. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2605-3_21 · Cited by 1
D-cycloserine en exposure in de behandeling van posttraumatische stressstoornis1
de Kleine, R. A., & van Minnen, A. (2012) · GZ - Psychologie · doi:10.1007/s41480-012-0059-2 · Cited by 1
Potentiation of the Startle Reflex as a Behavioral Measure of Anxiety
Gewirtz, J. C., & Radke, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_11 · Cited by 1
The role of endocannabinoid function in posttraumatic stress disorder
Gabbay, F. H., Choi, K. H., Wynn, G. H., & Ursano, R. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00011-4 · Cited by 1
Recent Advances in the Understanding and Treatment of Anxiety Disorders
Stein, D. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900025785 · Cited by 1
Die Neurobiologie und ihre Implikationen für die Sexualtherapie
Krüger, T. H. C. (2017) · Springer eBooks · doi:10.1007/978-3-662-54415-0_4 · Cited by 1
Treatment Resistance in Anxiety Disorder: Generalized Anxiety Disorder and Social Anxiety Disorder
Lee, K. S., & Lee, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_14 · Cited by 1
Functioning of the Core Neural Network in Fear and Extinction
Bennett, M. R., & Lagopoulos, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-91116-8_6 · Cited by 1
Cognitive Behavioral Therapy for Anxiety Disorders
Wieman, S. T., Kind, S., & Baker, A. W. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-30687-8_12 · Cited by 2
London, E., & Yoo, J. H. (2021) · Brain Sciences · doi:10.3390/brainsci11081073 · Cited by 1
Schmahl, C. G. (2009) · Springer eBooks · doi:10.1007/978-3-540-88489-7_4 · Cited by 1
Current and Experimental Treatments for Anxiety Disorders
Guastella, A. J., Norton, A., Alvares, G. A., & Song, Y. J. C. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0040 · Cited by 1
Quirk, G. J. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6434-1_73-3 · Cited by 1
Chapter 13. Theories of Interpersonal Therapy
Lipsitz‐Odess, I., Lipsitz, J. D., & Markowitz, J. C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg13 · Cited by 1
Chapter 6. Applications of Psychodynamic Psychotherapy to Specific Disorders
Leichsenring, F., & Steinert, C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg06 · Cited by 1
Chapter 26. How Our Mind Becomes Racialized
Stoute, B. J. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg26 · Cited by 1
Understanding Human Fear Extinction: Insights from Psychophysiology
Woodford, J., Riser, M., & Norrholm, S. D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_435 · Cited by 1
Davis, M. T., Asch, R., Weiss, E. R., Wagner, A., Fineberg, S. K., Nabulsi, N., Matuskey, D., Carson, R. E., & Esterlis, I. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.11.014 · Cited by 1
Self-citationOxytocin’s role in the interaction between emotion and cognitive control
Ganzel, A. R., Shalev, H., Hochman, S., Zultan, R., Cohen, N., & Naparstek, S. (2025) · Biological Psychology · doi:10.1016/j.biopsycho.2025.109004 · Cited by 2
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.2 · Cited by 1
Pharmacological enhancement of learning in exposure therapy
Ressler, K. J., Davis, M., & ROTHBAUM, B. O. (2007) · Elsevier eBooks · doi:10.1016/b978-012587421-2/50016-8 · Cited by 1
Self-citationFrom Treating Mental Dysfunction to Neuroenhancement
Koch, M. (2013) · Happiness studies book series · doi:10.1007/978-94-007-6609-9_8 · Cited by 1
Medikamentenabhängigkeit und Arbeit
Holzbach, R. (2013) · Springer eBooks · doi:10.1007/978-3-642-37117-2_9 · Cited by 1
ROTHBAUM, B. O., & Ressler, K. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.008 · Cited by 1
Self-citationTranslating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19205 · Cited by 1
Self-citationKoch, E. I., & Fernando, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70539-2_38 · Cited by 1
Pharmakotherapie bei Angsterkrankungen
Zwanzger, P. (2016) · PSYCH up2date · doi:10.1055/s-0041-101745 · Cited by 1
Quirk, G. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1997-6_73 · Cited by 1
Quirk, G. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-88832-9_73 · Cited by 1
Chapter 8. Techniques of Cognitive-Behavioral Therapy
Wright, J. H., Reis, J., & Casey, D. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg08 · Cited by 3
Anxiety Disorders: Social Anxiety Disorder and Specific Phobia
McCabe, R. E., Hood, H. K., & Antony, M. M. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch54 · Cited by 1
Conditioned Fear Extinction and Generalization in Posttraumatic Stress Disorder
Norrholm, S. D. (2011) · Defense Technical Information Center (DTIC) · doi:10.21236/ada555145 · Cited by 1
Behavioral and neural characterization of conditioned flavor -taste preferences
Golden, G. J. (2007) · Cited by 1
Obsessive‐Compulsive Disorder: Assessment and Treatment
Amitai Abramovitch, A., Elliott, C. M., Wilhelm, S., Steketee, G. S., & Wilson, A. C. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch51 · Cited by 1
Pharmacology of Fear Extinction
Davis, M., & Myers, K. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00758-0 · Cited by 1
Self-citationNew Approaches to Treatment of Schizophrenia by Enhancing N-methyl- d -aspartate Neurotransmission
Tsai, G. E. (2007) · Progress in Neurotherapeutics and Neuropsychopharmacology · doi:10.1017/s1748232107000055 · Cited by 1
Avoiding Treatment Failures in Obsessive Compulsive Disorder
Marques, L. M., Chosak, A., Phan, D.-M., Fama, J. M., Franklin, S. A., & Wilhelm, S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0612-0_8 · Cited by 1
The 'whole-animal approach' as a heuristic principle in neuroscience research
SERANI-MERLO, A., Paz, R. D., & Castillo, A. (2005) · Biological Research · doi:10.4067/s0716-97602005000400008 · Cited by 1
Yeh, S., Newman, B., Liewer, M., Pair, J., Treskunov, A., Parsons, T. D., Reger, G. M., Spitalnick, J. S., ROTHBAUM, B. O., & Rizzo, A. (2009) · Cited by 1
Self-citationPharmakologisch unterstützte Psychotherapie
Spitzer, M. (2006) · Nervenheilkunde · doi:10.1055/s-0038-1626444 · Cited by 1
Kaskas, M. M., Ryan, P. M., & Davis, T. E. (2017) · Wiley eBooks · doi:10.1002/9781118877142.ch3 · Cited by 1
Information Circulation in The Advanced Neural Activities of Central Neural SystemPreprint
Ma, F. (2020) · Preprints.org · doi:10.20944/preprints202008.0195.v1
Finnegan, S., Harrison, O. K., Booth, S., Dennis, A., Ezra, M., Harmer, C. J., Herigstad, M., Guillaume, B., Nichols, T. E., Rahman, N. M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4007187 · Cited by 1
(2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375070-9.00021-8 · Cited by 1
Pine, D. S. (2015) · Wiley eBooks · doi:10.1002/9781118381953.ch10 · Cited by 1
Guastella, A. J., & Alvares, G. A. (2012) · Wiley eBooks · doi:10.1002/9781119945901.ch5 · Cited by 1
Pauli, P. (2006) · Psychologische Rundschau · doi:10.1026/0033-3042.57.3.137 · Cited by 1
Specific phobias and agoraphobia
Norman, S. B., & Lang, A. J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.035
Novel roles for the GABAB receptor in anxiety and cocaine addiction
Sweeney, F. F. (2013) · Cork Open Research Archive (University College Cork, Ireland)
What Can Fear Conditioning Tell Us About Posttraumatic Stress Disorder?
Dębiec, J., & LeDoux, J. E. (2011) · Wiley eBooks · doi:10.1002/9781118083222.ch20
Koerner, N., Rogojanski, J., & Antony, M. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511781919.007
Panic Disorder: Assessment and Treatment
Szuhany, K. L., Kredlow, M. A., & Otto, M. W. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch46
de Leeuw, A. S. (2013) · Utrecht University Repository (Utrecht University)
NEUROBIOLOGICAL PERSPECTIVES ON TRAUMA
Kirmayer, L. J., Lemelson, R., & Barad, M. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511500008.004 · Cited by 1
Atypical Psychopharmacologic Strategies
Shatkin, J. P., & Janssen, A. C. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch15
Careers and ethical issues in the traumatic stress field
Ford, J. D., Grasso, D. J., Elhai, J. D., & Courtois, C. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801288-8.00012-1
Bos, M. G. N. (2014) · UvA-DARE (University of Amsterdam)
Thérapies comportementales et cognitives
Pélissolo, A., & Montefiore, D. (2009) · Elsevier eBooks · doi:10.1016/b978-2-294-70563-2.00003-x
Bruchey, A. K. (2006) · Texas ScholarWorks (Texas Digital Library)
Advances in the pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines
Kosten, T. R. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.013
Commentary on “Integrating the Psychoanalytic and Neurobiological Views of Panic Disorder”
Pincus, D. I. (2005) · Neuropsychoanalysis · doi:10.1080/15294145.2005.10773486
Memory improvement with the metabolic enhancer methylene blue
Wrubel, K. M. (2006) · Texas ScholarWorks (Texas Digital Library)
Hippocampal Circuitry Dysfunction in the 5-HT1A Knockout Mouse
Metzger, K. L. (2012) · ScholarlyCommons (University of Pennsylvania)
Jacobson, L. H. (2007) · edoc (University of Basel) · doi:10.5451/unibas-004290851
Plasticity of fear memory: a search for relapse prevention
Effting, M. (2011) · UvA-DARE (University of Amsterdam)
de Bitencourt, R. M. (2008)
Understanding the causes of anxiety
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.015
Aupperle, R. L. (2009) · KU ScholarWorks (The University of Kansas)
Medication Treatments for Social Anxiety Disorder
Shaywitz, J. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.3.foc273
Pharmakotherapie der Angststörungen
Ebner, C., & Hofmann, P. (2011)
Strategies for managing symptoms
Taylor, S. J., Bovell, C. V., & Collimore, K. C. (2006)
de Altura, M. (2008)
Clinical Implications Facilitation of Fear Extinction by D-Cycloserine: Theoretical and
Richardson, R., Ledgerwood, L., & Cranney, J. (2006)
cortexcircuits for fear and addiction overlap in prefrontal
Peters, J., Kalivas, P. W., & Quirk, G. J. (2009)
Neurogenesis and generalization: a new approach to stratify and treat anxiety
Klemenhagen, K. C., Sahay, A., & Hen, R. (2012)
Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder
Murrough, J. W., Schiller, D., & Charney, D. S. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00226
Michael, D. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781316422250.005
Translational approaches to the treatment of anxiety disorders
Gillespie, C. F., Weiss, T., & Ressler, K. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.003
Self-citationWingo, A. P., Almli, L. M., & Ressler, K. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00035-4
Self-citationSection summary and perspectives: Translational medicine in psychiatry
Coyle, J. T. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.007
Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders
Rodríguez, C. I., & Dakwar, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_9
Extinction, erasure, and the recovery of fear memories
Golkar, A. (2013)
Social Anxiety Disorder: Behavioural Characteristics Associated with the Cortisol Stress Response
Vaccarino, O. (2013) · TSpace (University of Toronto)
Pharmacologic Management of Comorbid Post-Traumatic Stress Disorder and Addictions
Shorter, D. I., Hsieh, J. J., & Kosten, T. R. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.150405
Innovative pharmakologische Strategien gegen Angststörungen
Kiebs, M., & Hurlemann, R. (2018) · NeuroTransmitter · doi:10.1007/s15016-018-6296-x
Neuroscience of Associative Learning
Weidemann, G., & McNally, G. P. (2011) · Oxford University Press eBooks · doi:10.1093/obo/9780199828340-0080
Complementary and Alternative Medicine for Trauma- and Stressor-Related Disorders
Wynn, G. H., & Benedek, D. M. (2018) · Oxford University Press eBooks · doi:10.1093/med/9780190457136.003.0024
Stovezky, Y. R., Gershkovich, M., Kayser, R. R., & Simpson, H. B. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.020
Neurocognitive mechanisms of d-cycloserine augmented single-session exposure therapy for anxietyPreprint
Reinecke, A., Nickless, A., Browning, M., & Harmer, C. (2019) · bioRxiv · doi:10.1101/615757
The influence of virtual reality exposure on social and phobic behaviours
Oing, T. (2019) · UBIR (University of Greater Manchester)
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
